>>The course of treatment for refractory
GIST is shorter than myeloma?<<
Could be; I have no idea.
>>wiw, Infinity once listed in a press release
Gleevec resistant GIST
Herceptin resistant breast cancer
Tarceva resistant lung cancer
Velcade resistant multiple myeloma<<
Thanks for that list; they are talking only monotherapy for all of those, right (though we now know monotherapy isn't feasible in MM)?.
>>I am curious which trials would enroll the fastest.<<
I haven't a clue.
>>Maybe Perkins said what she said simply because
Infinity has a partner in Medimmune, but Kosan
does not. <<
Well, that seems a stretch to me, if so. That's more a difference in partnering strategy; if the companies have similar expertise (hard to assess if INFI/MEDI's clinical development expertise in oncology is better than Kosan's, and if so, what difference it will make before Kosan partners) and sufficient resources, the partner won't affect the clinical development timeline that much. KOSN raised funds recently, so they can afford to partner later than Infinity did, thus capturing more of the profits. I was asking if INFI has outlined the strategy by which they'll get to market first or if it's still a secret (though again, the only plausible way, IMO, is to register from GIST PII).
Traveling again; may be out of touch for a couple of days. Happy Thanksgiving all!
Cheers, Tuck |
